Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma

BACKGROUND: Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma. Adding other active agents may enhance treatment efficacy. METHODS: The primary objective of this factorial phase II study was to determine if one of 3 potential chemotherapy ag...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Penas-Prado, Marta, Hess, Kenneth R., Fisch, Michael J., Lagrone, Lore W., Groves, Morris D., Levin, Victor A., De Groot, John F., Puduvalli, Vinay K., Colman, Howard, Volas-Redd, Gena, Giglio, Pierre, Conrad, Charles A., Salacz, Michael E., Floyd, Justin D., Loghin, Monica E., Hsu, Sigmund H., Gonzalez, Javier, Chang, Eric L., Woo, Shiao Y., Mahajan, Anita, Aldape, Kenneth D., Yung, W. K. Alfred, Gilbert, Mark R.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2015
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4288521/
https://ncbi.nlm.nih.gov/pubmed/25239666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou155
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky